US4440747A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease
Assignee: United States Department of Health and Human Services
•
Filing: 1982-02-19
•
Granted: 1984-04-03
•
Expires: 2002-02-19
Abstract
Abstract The receptor specificity of toxins can be altered by coupling the intact toxin to monoclonal antibodies directed to the cell surface antigen Thy 1.2. Monoclonal antibody Thy 1.2-ricin (or ricin A chain) is a pretreatment reagent used to eliminate graft-versus-host disease (GVHD) in bone marrow transplants.
Inventors
- 👤 David M. Neville Jr.
- 👤 Richard J. Youle
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:36
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2803; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/868
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
43 words
A process for the treatment of graft versus host disease comprising removing bone marrow cells from a murine donor; in vitro treating the donor cells with anti-thy 1.2-ricin in the presence of excess lactose; and injecting the treated cells into a murine recipient.
Claim 2
Dependent Claim
43 words
A process for the treatment of graft versus host disease comprising removing bone marrow cells from a murine donor; in vitro treating the donor cells with anti-thy 1.2-ricin in the presence of excess lactose; and injecting the treated cells into a murine recipient.
Claim 3
Dependent Claim
56 words
A process using monoclonal antibody anti-thy 1.2-ricin for the pretreatment of murine graft versus host disease comprising removing bone marrow cells from mice exhibiting graft versus host disease; combining in vitro said bone marrow cells with monoclonal antibody anti-thy 1.2-ricin in the presence of excess lactose; injecting said treated bone marrow cells into a murine recipient.
Claim 4
Dependent Claim
56 words
A process using monoclonal antibody anti-thy 1.2-ricin for the pretreatment of murine graft versus host disease comprising removing bone marrow cells from mice exhibiting graft versus host disease; combining in vitro said bone marrow cells with monoclonal antibody anti-thy 1.2-ricin in the presence of excess lactose; injecting said treated bone marrow cells into a murine recipient.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-04-03 | 1987-10-03 | 1988-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-04-03 | 1991-10-03 | 1992-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-04-03 | 1995-10-03 | 1996-04-03 | $7700.00 | Window Closed / Lapsed |